- Home
- CDLR vs MNKD Comparison
CDLR vs MNKD Comparison
Compare CDLR & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDLR | MNKD |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2023 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CDLR | MNKD |
|---|---|---|
| Price | $24.73 | $2.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.64 |
| AVG Volume (30 Days) | 76.3K | ★ 6.6M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $142.95 | $33.40 |
| Revenue Next Year | $70.44 | $16.48 |
| P/E Ratio | ★ $7.39 | $140.75 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $15.37 | $2.52 |
| 52 Week High | $26.79 | $6.51 |
Technical Indicators
Market Signals| Indicator | CDLR | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 23.75 |
| Support Level | $23.38 | N/A |
| Resistance Level | $25.21 | $6.08 |
| Average True Range (ATR) | 0.64 | 0.37 |
| MACD | -0.28 | -0.05 |
| Stochastic Oscillator | 35.66 | 7.79 |
Price Performance
Historical ComparisonAbout CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.